Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
323U66 SR in Major Depressive Disorder
NCT01138007Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2010
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of bupropion in major depressive disorder (MDD), sponsored by GSK. Started Jun 2010; status: completed.
02
Drugs
bupropion
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT01138007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01138007.